{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:13:00Z","timestamp":1770840780054,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40262-021-01049-3","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T02:03:06Z","timestamp":1624413786000},"page":"1605-1619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension"],"prefix":"10.1007","volume":"60","author":[{"given":"Roberta","family":"Bartolucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Ga\u00eblle","family":"Dosne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9nes","family":"Csonka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"P\u00e9rez-Ruixo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Magni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3079-6954","authenticated-orcid":false,"given":"Italo","family":"Poggesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"issue":"14","key":"1049_CR1","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMra040291","volume":"351","author":"M Humbert","year":"2004","unstructured":"Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425\u201336.","journal-title":"N Engl J Med"},{"issue":"5","key":"1049_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40262-015-0255-5","volume":"54","author":"PN Sidharta","year":"2015","unstructured":"Sidharta PN, Treiber A, Dingemanse J. Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan. Clin Pharmacokinet. 2015;54(5):457\u201371.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1049_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1517\/14740338.2014.859674","volume":"13","author":"J Dingemanse","year":"2014","unstructured":"Dingemanse J, Sidharta PN, Maddrey WC, Rubin LJ, Mickail H. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf. 2014;13(3):391\u2013405.","journal-title":"Expert Opin Drug Saf"},{"key":"1049_CR4","unstructured":"US Food and Drug Administration. Opsumit\u00ae (macitentan) prescribing information. 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/204410s017lbl.pdf. Accessed 26 Nov 2020."},{"key":"1049_CR5","unstructured":"EMC. Summary of product characteristics: Opsumit (macitentan). 2020. https:\/\/www.medicines.org.uk\/emc\/product\/5223\/smpc. Accessed 26 Nov 2020."},{"issue":"8","key":"1049_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40262-013-0063-8","volume":"52","author":"J Atsmon","year":"2013","unstructured":"Atsmon J, Dingemanse J, Shaikevich D, Volokhov I, Sidharta PN. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013;52(8):685\u201392.","journal-title":"Clin Pharmacokinet"},{"key":"1049_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.pupt.2018.02.005","volume":"49","author":"A Krause","year":"2018","unstructured":"Krause A, Zisowsky J, Dingemanse J. Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension. Pulm Pharmacol Ther. 2018;49:140\u20136.","journal-title":"Pulm Pharmacol Ther"},{"issue":"10","key":"1049_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00228-011-1043-2","volume":"67","author":"PN Sidharta","year":"2011","unstructured":"Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol. 2011;67(10):977\u201384.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1049_CR9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/jcph.152","volume":"53","author":"PN Sidharta","year":"2013","unstructured":"Sidharta PN, van Giersbergen PL, Dingemanse J. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. J Clin Pharmacol. 2013;53(11):1131\u20138.","journal-title":"J Clin Pharmacol"},{"key":"1049_CR10","unstructured":"US Food and Drug Administration. Clinical pharmacology and biopharmaceutics review. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204410Orig1s000ClinPharmR.pdf. Accessed 26 Nov 2020."},{"issue":"5\u20136","key":"1049_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000351704","volume":"91","author":"S Bruderer","year":"2013","unstructured":"Bruderer S, Marjason J, Sidharta PN, Dingemanse J. Pharmacokinetics of macitentan in Caucasian and Japanese subjects: the influence of ethnicity and sex. Pharmacology. 2013;91(5\u20136):331\u20138.","journal-title":"Pharmacology"},{"issue":"5","key":"1049_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40256-014-0081-4","volume":"14","author":"LY Ahn","year":"2014","unstructured":"Ahn LY, Kim SE, Yi S, et al. Pharmacokinetic\u2013pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects. Am J Cardiovasc Drugs. 2014;14(5):377\u201385.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"1049_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jcph.193","volume":"54","author":"PN Sidharta","year":"2014","unstructured":"Sidharta PN, Lindegger N, Ul\u010d I, Dingemanse J. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment. J Clin Pharmacol. 2014;54(3):291\u2013300.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1049_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ejps.2009.09.005","volume":"38","author":"O Kummer","year":"2009","unstructured":"Kummer O, Haschke M, Hammann F, et al. Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. Eur J Pharm Sci. 2009;38(4):384\u20138.","journal-title":"Eur J Pharm Sci"},{"key":"1049_CR15","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ, editors. NONMEM 7.3.0 users guide (1989\u20132014). Ellicott City: Icon Development Solutions."},{"key":"1049_CR16","unstructured":"R Archive Network. http:\/\/cran.r-project.org. Accessed 26 Nov 2020."},{"issue":"3","key":"1049_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40262-015-0322-y","volume":"55","author":"R de Kanter","year":"2016","unstructured":"de Kanter R, Sidharta PN, Delahaye S, et al. Physiologically-based pharmacokinetic modeling of macitentan: prediction of drug\u2013drug interactions. Clin Pharmacokinet. 2016;55(3):369\u201380.","journal-title":"Clin Pharmacokinet"},{"key":"1049_CR18","unstructured":"US Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm072123.pdf. Accessed 26 Nov 2020."},{"key":"1049_CR19","unstructured":"US Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired renal function: study design, data analysis, and impact on dosing and labeling. 2010. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm204959.pdf. Accessed 26 Nov 2020."},{"issue":"7","key":"1049_CR20","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1111\/bcp.13577","volume":"84","author":"XS Xu","year":"2018","unstructured":"Xu XS, Yuan M, Zhu H, et al. Full covariate modelling approach in population pharmacokinetics: understanding the underlying hypothesis tests and implications of multiplicity. Br J Clin Pharmacol. 2018;84(7):1525\u201334.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1049_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"issue":"8","key":"1049_CR22","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/psp4.12422","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ. NONMEM tutorial part II: estimation methods and advanced examples. CPT Pharmacomet Syst Pharmacol. 2019;8(8):538\u201356.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"4","key":"1049_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM. J Pharmacokinet Pharmacodyn. 2008;35(4):401\u201321.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"1049_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-019-2723-3","volume":"37","author":"AK Volz","year":"2020","unstructured":"Volz AK, Dingemanse J, Krause A, Lehr T. Target-mediated population pharmacokinetic modeling of endothelin receptor antagonists. Pharm Res. 2020;37(1):1\u201312.","journal-title":"Pharm Res"},{"issue":"9","key":"1049_CR25","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3109\/00498254.2012.664665","volume":"42","author":"S Bruderer","year":"2012","unstructured":"Bruderer S, Hopfgartner G, Seiberling M, et al. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica. 2012;42(9):901\u201310.","journal-title":"Xenobiotica"},{"key":"1049_CR26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2147\/DDDT.S199051","volume":"13","author":"PN Sidharta","year":"2019","unstructured":"Sidharta PN, Melchior M, Kankam MK, Dingemanse J. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects. Drug Des Dev Ther. 2019;13:949\u201364.","journal-title":"Drug Des Dev Ther"},{"key":"1049_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332.","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01049-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01049-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01049-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T06:46:50Z","timestamp":1699166810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01049-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01049-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"assertion":[{"value":"9 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RB, AGD, DC, JJPR, PM, and IP contributed to the design of the work, the acquisition of the data, the analysis or interpretation of the data, and the preparation of the manuscript. All authors have approved the submitted version and are accountable for it.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"Anne-Ga\u00eblle Dosne, D\u00e9nes Csonka, Juan\u00a0Jos\u00e9 P\u00e9rez-Ruixo, and Italo Poggesi\u00a0were employees and shareholders of Janssen Pharmaceutical Companies at the time this analysis was conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The clinical studies were supported by research funding from Actelion (currently, a Janssen pharmaceutical company).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The studies were conducted in accordance with principles for human experimentation as defined in the Declaration of Helsinki and were approved by the human investigational review board of the study center and by the competent authority of the country.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from each subject before enrollment in the studies, after being advised of the potential risks and benefits, as well as the investigational nature of the studies.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The NONMEM script of the final model is available as ESM.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}